You state "He is an ADVISOR (insider)..."
Again, carelessness with terms and facts.
An advisor is a consultant on specific issues, for example, mechanism of action of Sucanon and can use his expertise in treating diabetes to study different treatments, combination of medicines to most effectively treat prediabetics or type 2 diabetics.
An insider has specific holdings or positions (like CEO, CFO, director) within the company that require disclosure of stock purchase/sale or other actions. I have previously provided a link to that definition and information.
Compensation for that advisory role is routine Your previous comment "if the Dr is involved he could lose his license for working on this ' trial' while being a shareholder" and the constant false and damaging comments about Dr. Rojas show complete ignorance of medical procedure regarding conduct and presentation of medical research. Compensation/consultancy/financial relationships of any kind including research grants are routinely declared by researchers on publication and presentation. That is a fact and adopted by most all medical societies, and I witness it on a regular basis at meetings and review of publications to direct my medical treatment decisions.
Dr Rojas study presented at EASD annual meeting 2013 in Barcelona Spain: 97 pre diabetic adult patients (HbA1C 5.7 to 6.2) 12 weeks with normalization of HbA1C (below 5.7) in 81% of study population and decrease in weight and visceral body fat, in contrast to weight gain in alternative medications. No "obvious conflict" of the researcher acting as a consultant to ROTH since any reputable professional organization allows researchers to present results at meetings when declaring a financial relationship or consultancy regarding the company or product.
The science is in fact done right, publicly verifiable and speaks for itself. The results of Sucanon testing, in addition to the risks of alternative treatments make Sucanon, IMO, an excellent first line choice for pre diabetic and non insulin dependent diabetics due to Sucanon's efficacy and safety. That is the reason I am involved as a shareholder. If this information is effectively communicated to prescribers and the burgeoning diabetic populations throughout the world (50% of population diabetic or prediabetic in USA alone) the potential of Sucanon is enormous.
I'm looking forward to the results of the 12 week trial in Mexico to satisfy the India regulatory application. The more Sucanon is studied, the more complete the verification of its safety and efficacy.
